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Over 1.5 million new cases of non-small cell lung cancer 
(NSCLC), a highly aggressive disease, are registered 
worldwide every year (1). Until the 1980s, treatment 
generally yielded poor outcomes (2), and prognosis was 
only good for early stages of operable disease. However, 
advances in targeted molecular therapy since 2005 have 
brought new hope to patients with advanced NSCLC, 
especially those harboring the epidermal growth factor receptor 
(EGFR) mutation in exons 18, 19 and 21 (3). As a result, the 
median overall survival (OS) of a small group of patients with 
advanced NSCLC increased from 10 to 18–36 months (2). 
The fusion of the EML4 gene (echinoderm microtubule-
associated protein-like 4) and the ALK gene (anaplastic 
lymphoma kinase) affects the outcome of almost 5% of 
patients with this phenotype (2,4). Indeed, patients with 
this profile presented a very good overall response rate 
(74%) when submitted to treatment with crizotinib (an 
ALK-inhibitor) in the clinical trial PROFILE 1014 (5). 
More recently, resistance mechanisms to EGFR and 
ALK inhibitors have raised concerns regarding disease 
progression. However, the use of checkpoint inhibitors 
target ing  the  mechanisms  of  CTLA4 (cytotox ic 
T-lymphocyte-associated protein 4) and PD1/PDL1 
(programmed cell death protein 1 and ligand) has become 
a cornerstone in the treatment of NSCLC (6,7). Several 
drugs (e.g., ipilimumab, pembrolizumab and nivolumab) 
have been shown to be efficient and safe in the treatment 
of advanced NSCLC, though their mechanisms are still 
not fully understood (7,8). Quoix et al. recently published 
promising results from phase 2b/3 TIME trial (9). TG4010 
is a modified vaccinia Ankara expressing MUC1 and 
interleukin 2. In addition, baseline levels of CD16, CD56 
and CD69 (triple-positive activated lymphocytes; TrPAL) 
were measured to evaluate their potential as predictive 
biomarkers. The authors recruited 222 previously untreated 
stage IV NSCLC patients without a known activating 
EGFR mutation and with MUC1 expression in at least 
50% of tumor cells, stratified them according to baseline 
TrPAL levels and allocated them to two groups (TG4010 + 
chemotherapy vs. placebo + chemotherapy) of 111 patients 
each. Progression-free survival (PFS) was longer in the 
former than in the latter (5.9 vs. 5.1 months, P=0.019), 
but overall survival (OS) was statistically similar in the 
two groups (12.7 vs. 10.6 months, respectively; P=0.055). 
In patients with non-squamous histology and TrPAL 
levels below the upper limit of normal (ULN), survival 
was longer when TG4010 was administered (PFS: 6.0 vs. 
4.9 months, P=0.0033; OS: 15.1 vs. 10.3 months, P=0.0072). 
No significant difference was observed between the groups 
with regard to PDL1 levels, but patients in the TG4010 
group experienced more grade 1 and 2 adverse events 
(fatigue: 51% vs. 47%; nausea: 46% vs. 40%; injection 
site reaction: 33% vs. 4%; dyspnea: 23% vs. 8%). Thus, in 
clinical practice premedication should be combined with 
appropriate anti-emetics, anti-histaminics and steroids 
to minimize adverse reactions and increase tolerability. 
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Considering the good results of this trial for patients with 
non-squamous histology and TrPAL levels below ULN, 
TG4010 appears to be a promising alternative to extend 
OS in the first-line setting for patients without the EGFR 
mutation or ALK fusion. In addition, nivolumab and 
pembrolizumab showed activity against advanced NSCLC 
in a second line setting; however a strong biomarker 
(PDL1 expression) unfortunately was not validated to this 
setting, providing a lack of efficacy information for those 
approaches. As for toxicity, the potential adverse effects of 
these new drugs require further study to ensure tolerability 
and quality of life. The validation of TrPAL levels as a new 
biomarker is urgently needed to tailor therapy for NSCLC 
patients and may represent the beginning of a new era in 
immunotherapy for NSCLC.
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